HistologiX will be attending the MarketsandMarkets Next Gen Immuno-Oncology Congress. Visit us at stand #2 to meet our team and learn about how we can support your immuno-oncology research. Come see us to discuss how our services can help drive your programmes forward.
“The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectviely than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.”
Visit stand #2 at this meeting to meet our team and discuss how we might be able to drive your immuno-oncology programmes.